Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

BACKGROUND: The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the KRAS G12C-specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequency, clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Si-Yang, Sun, Hao, Zhou, Jia-Ying, Jie, Guang-Ling, Xie, Zhi, Shao, Yang, Zhang, Xian, Ye, Jun-Yi, Chen, Chun-Xiang, Zhang, Xu-Chao, Zhou, Qing, Yang, Jin-Ji, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318746/
https://www.ncbi.nlm.nih.gov/pubmed/32607238
http://dx.doi.org/10.1186/s40364-020-00199-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318746/
https://www.ncbi.nlm.nih.gov/pubmed/32607238
http://dx.doi.org/10.1186/s40364-020-00199-z

Ejemplares similares